Shares of this vaccine maker have returned -13.6% over the past month versus the Zacks S&P 500 composite's +1% change. The Zacks Medical - Biomedical and Genetics industry, to which Novavax ...

Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced progress in Q4 2024 advancing its corporate growth strategy through ...

Novavax (NVAX) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.

The first human bird flu death in the US has Moderna's vaccine development in focus for investors this week. Recently, Zacks.com users have been paying close attention to Novavax (NVAX). This makes it ...

Novavax (NVAX) closed the most recent trading day at $8.45, moving +0.24% from the previous trading session. The stock trailed the S&P 500, which registered a daily gain of 0.72%. Meanwhile, the Dow ...

The UK approval marks the fourth regulatory approval Valneva has received for its single-shot chikungunya vaccine. The vaccine is currently approved in the United States (U.S.) 2, Europe 3 and Canada ...

Valneva (VALN) announced that the Medicines and Healthcare products Regulatory Agency or MHRA has granted marketing authorization in the United ...

despite his denial of the anti-vaccine label. His potential confirmation as head of the department that oversees the FDA and healthcare programs has sparked unease among investors in vaccine ...

despite his denial of the anti-vaccine label. His potential confirmation as head of the department that oversees the FDA and healthcare programs has sparked unease among investors in vaccine ...

Back in November 2023, pharmaphorum travelled to Uppsala, Sweden, for a Novavax press conference, the company celebrating a decade of doing what it does best: vaccines. From COVID-19 to malaria ...